Darifenacin hydrobromide NEW

Darifenacin hydrobromide is a medication used to treat overactive bladder (OAB). It belongs to the antimuscarinic (anticholinergic) drug class, acting by blocking specific receptors in the bladder to reduce overactivity.

Key Details

• Mechanism of Action: Targets muscarinic M3 receptors in the bladder detrusor muscle. Blocking these receptors relaxes the muscle, decreasing urinary frequency, urgency, and urge incontinence (uncontrolled leakage).

• Indications: Specifically approved for OAB symptoms, including frequent urination (≥8 times daily), sudden strong urges to urinate, and urge-related leakage.

• Formulation: Available as extended-release tablets (once-daily dosing), designed to release the drug gradually for sustained effect.

Important Safety & Usage Notes

• Contraindications: Not for use in people with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, or severe liver impairment.

• Common Side Effects: Dry mouth, constipation, dry eyes, and blurred vision (typical of anticholinergics). Less common effects include urinary hesitation, abdominal pain, and dizziness.

• Precautions: Use cautiously in those with liver/kidney impairment, gastrointestinal disorders (e.g., irritable bowel syndrome), or cognitive issues (may worsen confusion in older adults). Avoid alcohol and other anticholinergic drugs to reduce side effect risk.

• Drug Interactions: May interact with potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) or inducers (e.g., rifampin), requiring dosage adjustments.

Clinical Considerations

• It is a prescription-only medication, so it must be used under a healthcare provider’s supervision.

• Dosage is typically started low and adjusted based on tolerance and symptom improvement.

• It may take 2–4 weeks to experience full therapeutic benefits.